A phase 1/2, dose-escalation trial of deferasirox for the treatment of iron overload in HFE-related hereditary hemochromatosis

Abstract

Hereditary hemochromatosis (HH) is characterized by increased intestinal iron absorption that may result in iron overload. Although phlebotomy is widely practiced, it is poorly tolerated or contraindicated in patients with anemias, severe heart disease, or poor venous access, and compliance can vary. The once-daily, oral iron chelator, deferasirox (Exjade) may provide an alternative treatment option. Patients with HH carrying the HFE gene who were homozygous for the Cys282Tyr mutation, serum ferritin levels of 300-2000 ng/mL, transferrin saturation ≥ 45%, and no known history of cirrhosis were enrolled in this dose-escalation study to characterize the safety and efficacy of deferasirox, comprising a core and an extension phase (each 24 weeks). Forty-nine patients were enrolled and received starting deferasirox doses of 5 (n = 11), 10 (n = 15), or 15 (n = 23) mg/kg/day. Adverse events were generally dose-dependent, the most common being diarrhea, headache, and nausea (n = 18, n = 10, and n = 8 in the core and n = 1, n = 1, and n = 0 in the extension, respectively). More patients in the 15 mg/kg/day than in the 5 or 10 mg/kg/day cohorts experienced increases in alanine aminotransferase and serum creatinine levels during the 48-week treatment period; six patients had alanine aminotransferase > 3 × baseline and greater than the upper limit of normal range, and eight patients had serum creatinine > 33% above baseline and greater than upper limit of normal on two consecutive occasions. After receiving deferasirox for 48 weeks, median serum ferritin levels decreased by 63.5%, 74.8%, and 74.1% in the 5, 10, and 15 mg/kg/day cohorts, respectively. In all cohorts, median serum ferritin decreased to < 250 ng/mL.

Conclusion: Deferasirox doses of 5, 10, and 15 mg/kg/day can reduce iron burden in patients with HH. Based on the safety and efficacy results, starting deferasirox at 10 mg/kg/day appears to be most appropriate for further study in this patient population.

Figures

Figure 1

Patient disposition in the core and extension study. *The 5 mg/kg/day dose reduced serum ferritin in only three patients; the other six patients in this dose cohort received 10 mg/kg/day at the start of the extension (all but one patient experienced serum ferritin levels

Figure 2

Median serum ferritin in (A) patients enrolled in the core study and (B) patients who completed the core and continued into the extension study. BL, baseline. Note that the 5 mg/kg/day dose reduced serum ferritin in three patients; the other six patients in this dose cohort received 10 mg/kg/day at the start of the extension (all but one patient experienced serum ferritin levels

Figure 3

Scatter plots of baseline serum ferritin versus worst ALT relative change (%) during (A) 24 weeks of treatment and (B) 48 weeks of treatment; and worst serum creatinine relative change (%) during (C) 24 weeks of treatment and (D) 48 weeks of treatment, by dose cohort and ULN.

Figure 4

Individual patient examples of the relationship between serum ferritin and (A) ALT and (B) serum creatinine.